AU2017230437B2 - Urea compound, preparation method therefor and medical use thereof - Google Patents

Urea compound, preparation method therefor and medical use thereof Download PDF

Info

Publication number
AU2017230437B2
AU2017230437B2 AU2017230437A AU2017230437A AU2017230437B2 AU 2017230437 B2 AU2017230437 B2 AU 2017230437B2 AU 2017230437 A AU2017230437 A AU 2017230437A AU 2017230437 A AU2017230437 A AU 2017230437A AU 2017230437 B2 AU2017230437 B2 AU 2017230437B2
Authority
AU
Australia
Prior art keywords
phenyl
benzimidazol
tert
butyl
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017230437A
Other languages
English (en)
Other versions
AU2017230437A1 (en
Inventor
Meifeng JIANG
Jutong Si
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ancureall Pharmaceutical Shanghai Co Ltd
Original Assignee
Ancureall Pharmaceutical Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ancureall Pharmaceutical Shanghai Co Ltd filed Critical Ancureall Pharmaceutical Shanghai Co Ltd
Publication of AU2017230437A1 publication Critical patent/AU2017230437A1/en
Application granted granted Critical
Publication of AU2017230437B2 publication Critical patent/AU2017230437B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2017230437A 2016-03-11 2017-03-10 Urea compound, preparation method therefor and medical use thereof Active AU2017230437B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610142049.XA CN107176951A (zh) 2016-03-11 2016-03-11 一种脲类化合物、其制备方法及其医药用途
CN201610142049.X 2016-03-11
PCT/CN2017/076265 WO2017152874A1 (zh) 2016-03-11 2017-03-10 一种脲类化合物、其制备方法及其医药用途

Publications (2)

Publication Number Publication Date
AU2017230437A1 AU2017230437A1 (en) 2018-09-06
AU2017230437B2 true AU2017230437B2 (en) 2020-11-26

Family

ID=59790078

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017230437A Active AU2017230437B2 (en) 2016-03-11 2017-03-10 Urea compound, preparation method therefor and medical use thereof

Country Status (10)

Country Link
US (1) US10647680B2 (ja)
EP (1) EP3424924B1 (ja)
JP (1) JP6927994B2 (ja)
KR (1) KR102430942B1 (ja)
CN (2) CN107176951A (ja)
AU (1) AU2017230437B2 (ja)
DK (1) DK3424924T3 (ja)
HK (1) HK1258545A1 (ja)
RU (1) RU2741596C2 (ja)
WO (1) WO2017152874A1 (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252350A1 (en) 2016-03-03 2017-09-07 Cornell University Small molecule ire1-alpha inhibitors
CN107176951A (zh) 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CN110016014B (zh) * 2018-01-08 2023-02-17 中国科学院上海药物研究所 Ezh2抑制剂及其制备和抗肿瘤治疗中的应用
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
TW202043205A (zh) 2018-12-31 2020-12-01 美商拜歐米富士恩有限公司 Menin-mll相互作用之抑制劑
KR20220062366A (ko) * 2019-09-26 2022-05-16 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도
JP7260718B2 (ja) * 2019-11-29 2023-04-18 メッドシャイン ディスカバリー インコーポレイテッド ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
WO2022017442A1 (zh) * 2020-07-24 2022-01-27 恩瑞生物医药科技（上海）有限公司 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042495A1 (en) * 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
EP1724258A1 (en) * 2004-02-23 2006-11-22 Chugai Seiyaku Kabushiki Kaisha Heteroarylphenylurea derivative
WO2007112093A2 (en) * 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
CN102153551A (zh) * 2010-04-02 2011-08-17 济南海乐医药技术开发有限公司 基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
CN102319242A (zh) * 2011-10-13 2012-01-18 济南海乐医药技术开发有限公司 吲唑双芳基脲化合物作为蛋白激酶抑制剂的应用
WO2012068406A2 (en) * 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
CN103450152A (zh) * 2012-06-04 2013-12-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
WO2015043492A1 (en) * 2013-09-26 2015-04-02 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and uses thereof in medicine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1567393A (en) * 1925-03-16 1925-12-29 Schlaich Herman Radiator cap
EP0242322B1 (en) * 1986-03-18 1992-12-16 Sandoz Ag Phenylureas
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
CN101239978A (zh) * 2008-03-05 2008-08-13 南方医科大学 一种咪唑并吡啶类化合物
CN103864792B (zh) * 2012-12-12 2017-01-18 山东亨利医药科技有限责任公司 作为酪氨酸激酶抑制剂的含氮并环类化合物
CN107176951A (zh) 2016-03-11 2017-09-19 恩瑞生物医药科技（上海）有限公司 一种脲类化合物、其制备方法及其医药用途

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042495A1 (en) * 2003-10-21 2005-05-12 Imclone Systems Incorporated (benzimidazol-2-yl)-phenyl-phenyl-urea compounds and methods for inhibiting heparanase activity
EP1724258A1 (en) * 2004-02-23 2006-11-22 Chugai Seiyaku Kabushiki Kaisha Heteroarylphenylurea derivative
WO2007112093A2 (en) * 2006-03-23 2007-10-04 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
CN102153551A (zh) * 2010-04-02 2011-08-17 济南海乐医药技术开发有限公司 基于吲唑或氮杂吲唑的双芳基脲或硫脲类结构抗肿瘤药物
WO2012068406A2 (en) * 2010-11-18 2012-05-24 Ligand Pharmaceuticals Incorporated Use of hematopoietic growth factor mimetics
CN102319242A (zh) * 2011-10-13 2012-01-18 济南海乐医药技术开发有限公司 吲唑双芳基脲化合物作为蛋白激酶抑制剂的应用
CN103450152A (zh) * 2012-06-04 2013-12-18 济南海乐医药技术开发有限公司 基于吲唑、吲哚或氮杂吲唑、氮杂吲哚的双芳基脲类结构抗肿瘤药物
WO2015043492A1 (en) * 2013-09-26 2015-04-02 Sunshine Lake Pharma Co., Ltd. Substituted urea derivatives and uses thereof in medicine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHAO CUI-RONG ET AL, "Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 7, pages 1989 - 1992 *

Also Published As

Publication number Publication date
KR20180132664A (ko) 2018-12-12
HK1258545A1 (zh) 2019-11-15
JP2019507779A (ja) 2019-03-22
RU2741596C2 (ru) 2021-01-27
EP3424924A1 (en) 2019-01-09
EP3424924B1 (en) 2023-05-24
RU2018131539A (ru) 2020-04-13
JP6927994B2 (ja) 2021-09-01
US10647680B2 (en) 2020-05-12
DK3424924T3 (da) 2023-08-28
EP3424924A4 (en) 2019-08-07
KR102430942B1 (ko) 2022-08-08
RU2018131539A3 (ja) 2020-04-13
CN109071523B (zh) 2022-05-31
BR112018016554A2 (pt) 2018-12-26
AU2017230437A1 (en) 2018-09-06
CN109071523A (zh) 2018-12-21
WO2017152874A1 (zh) 2017-09-14
US20190047964A1 (en) 2019-02-14
CN107176951A (zh) 2017-09-19

Similar Documents

Publication Publication Date Title
AU2017230437B2 (en) Urea compound, preparation method therefor and medical use thereof
US10478423B2 (en) Substituted indazole derivatives active as kinase inhibitiors
RU2581834C1 (ru) Новое пиперидиновое соединение или его соль
EA024824B1 (ru) Соединения-ингибиторы raf
ES2930106T3 (es) Compuesto derivado de pirrol-piridina, procedimiento para preparar el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o el tratamiento de enfermedades relacionadas con la proteína quinasa
EP3844166B1 (en) Substituted macrocycles useful as kinase inhibitors
EP3176160A1 (en) Pyridine-substituted 2-aminopyridine protein kinase inhibitors
JP2022538767A (ja) アセチルＣｏＡシンテターゼ２（ＡＣＳＳ２）阻害剤およびそれを使用する方法
JP6933644B2 (ja) アンドロゲン受容体拮抗薬
BR112021015813A2 (pt) Derivado de 7h-pirrolo[2,3-d]pirimidina-4-amina
KR20220008313A (ko) 퀴나졸리논계 화합물의 결정형 및 이의 제조방법
CN107216319B (zh) 一种2，4-二氨基嘧啶类衍生物、其制备方法及用途
BR112018016554B1 (pt) Composto de uréia, método de preparação do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
Fu et al. Structure-based drug design, synthesis, and biological evaluation of novel 1, 3, 5-triazine or pyrimidine derivatives containing benzoyl hydrazine moiety as PI3Kα selective inhibitors
WO2023046114A1 (zh) 蝶啶酮衍生物及其应用
WO2023155760A1 (zh) 一种药物组合物及所含活性成分化合物的制备方法
US20240199597A1 (en) Small molecules for the treatment of kinase-related diseases
CN115490640A (zh) 取代的苯并咪唑类化合物及包含该化合物的组合物及其用途
BR112017022243B1 (pt) Formas cristalinas do composto inibidor de fgfr4 cristalino, método para preparar uma forma cristalina e composição farmacêutica e usos terapêuticos das mesmas

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)